Permira sells Irish medical firm Creganna to TE Connectivity, makes 3.4x

Permira, the global investment firm, has announced  that a company backed by the Permira IV fund has entered into a definitive agreement to sell Creganna Medical (“Creganna” or the “Company”), a global manufacturing leader of delivery devices for the minimally invasive vascular surgery market, to TE Connectivity (NYSE:TEL) for US$895million in an all cash transaction.


Since being acquired by the Permira funds in 2010, Creganna was significantly transformed from a medical component manufacturer to a global leader in end-to-end manufacturing for the minimally invasive vascular surgery market. During that period, Creganna grew revenue from $131m in 2010 to $249m in 2015. This outcome was achieved through the recruitment of a world class management team, two strategic acquisitions – Precision Wire Components and ABT- that shaped an end-to-end offering, a global footprint and a competitive cost position as well as positioning the company as a leader in two high growth markets – electrophysiology and structural heart.


Mike Garland of Permira commented: “We are very proud to have worked with Creganna to develop its business into high growth markets, expand its global footprint, enhance its technical capabilities and deepen its customer partnerships over the past five years. This investment demonstrates our strategy to partner with market-leading, multi-national businesses with strong growth potential and support management teams to achieve their international growth ambitions, while at the same time create attractive returns for the Permira funds’ investors. We will continue to look for opportunities to partner with innovative outsourcing businesses servicing the medical devices industry and we wish Creganna every success with its new strategic owner TE Connectivity.”


Chip Hance, CEO of Creganna Medical, added: “We are pleased to be joining TE Connectivity to continue our journey to become the leading supplier of minimally invasive medical device delivery and access solutions for interventional medicine. With Permira’s support, we have been able to focus our efforts on critical markets, make the necessary investments and achieve strong results over the last few years. Now we are ready to take the next step in the evolution of the business. In addition to Permira, I’d like to thank the more than 2,000 staff throughout the world whose commitment has enabled Creganna to advance and be true to our medical device customers, physicians and patients that depend on the work we do.”


The sale of Creganna marks the second divestment managed by the global Healthcare team in a few months and follows last years’ sale of the world’s leading aquatic health group


Pharmaq to Zoetis Inc. The team was established in 2008 and is led by Mubasher Sheikh. Piper Jaffray acted as exclusive financial adviser to the Permira funds and Skadden, Arps, Slate, Meagher & Flom LLP acted as legal advisers. The sale is subject to regulatory approvals and other customary closing conditions and is expected to complete in Q2’16.


Source: Permira Press Release

Email this to someoneShare on LinkedInShare on FacebookTweet about this on TwitterShare on Google+